Literature DB >> 12724218

Methylation-sensitive representational difference analysis and its application to cancer research.

Atsushi Kaneda1, Daiya Takai, Michio Kaminishi, Eriko Okochi, Toshikazu Ushijima.   

Abstract

Methylation-sensitive representational difference analysis (MS-RDA) was previously established to detect differences in the methylation status of two genomes. This method uses the digestion of genomic DNA with a methylation-sensitive restriction enzyme, HpaII, and PCR to prepare "HpaII-amplicons," followed by RDA. An HpaII-amplicon prepared using betaine and reverse electrophoresis was enriched 3.6-fold (compared with the HpaII-amplicon prepared by the original method) with DNA fragments originating from CpG islands (CGIs). As for the specificity of MS-RDA, it was shown that DNA fragments that are unmethylated in the tester and almost completely methylated in the driver are efficiently isolated. This indicated that genes that are in biallelic methylation or in monoallelic methylation with loss of the other allele are efficiently isolated. Further, by use of two additional methylation-sensitive six-base recognition restriction enzymes, SacII and NarI, more DNA fragments were isolated from CGIs in the 5' regions of genes. After analysis of human lung, gastric, and breast cancers, 12 genes were seen to be silenced and additional genes seen to show decreased expression in association with methylation of genomic regions outside CGIs in the 5' regions of genes. MS-RDA is effective in identifying silenced genes in various cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724218     DOI: 10.1111/j.1749-6632.2003.tb05968.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Conference report--highlights of the 6th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association.

Authors:  Kris Novak
Journal:  MedGenMed       Date:  2004-03-03

2.  Methylation of multiple genes in gastric glands with intestinal metaplasia: A disorder with polyclonal origins.

Authors:  Mami Mihara; Yukinari Yoshida; Tetsuya Tsukamoto; Ken-ichi Inada; Yukihiro Nakanishi; Yukiko Yagi; Kohzoh Imai; Takashi Sugimura; Masae Tatematsu; Toshikazu Ushijima
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

3.  Isolation and bioinformatics analysis of differentially methylated genomic fragments in human gastric cancer.

Authors:  Ai-Jun Liao; Qi Su; Xun Wang; Bin Zeng; Wei Shi
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 4.  A review of the evolution of viviparity in squamate reptiles: the past, present and future role of molecular biology and genomics.

Authors:  Bridget F Murphy; Michael B Thompson
Journal:  J Comp Physiol B       Date:  2011-05-15       Impact factor: 2.200

5.  Age-related DNA methylation changes for forensic age-prediction.

Authors:  Shao Hua Yi; Yun Shu Jia; Kun Mei; Rong Zhi Yang; Dai Xin Huang
Journal:  Int J Legal Med       Date:  2014-11-16       Impact factor: 2.686

6.  Maps of cis-Regulatory Nodes in Megabase Long Genome Segments are an Inevitable Intermediate Step Toward Whole Genome Functional Mapping.

Authors:  Lev G Nikolaev; Sergey B Akopov; Igor P Chernov; Eugene D Sverdlov
Journal:  Curr Genomics       Date:  2007-04       Impact factor: 2.236

Review 7.  DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus.

Authors:  Keisuke Matsusaka; Sayaka Funata; Masashi Fukayama; Atsushi Kaneda
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

8.  Epigenomics in cancer management.

Authors:  Fabricio F Costa
Journal:  Cancer Manag Res       Date:  2010-10-27       Impact factor: 3.989

9.  DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers.

Authors:  J Ying; F F Poon; J Yu; H Geng; A H Y Wong; G-H Qiu; H K Goh; S Y Rha; L Tian; A T C Chan; J J Y Sung; Q Tao
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.